Bayer

News

Bayer cues up filings for rival to Astellas’ menopause drug

Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall

News

Bayer CEO pulls back from breakup of ‘badly broken’ group

Bayer chief executive Bill Anderson pulled no punches in his assessment of the company at its annual results update, saying it is “badly broken” by patent losses, litigati

News

Bayer pays $310m for Euro rights to ATTR therapy acoramidis

Bayer has shored up its near-term pipeline by acquiring European rights to acoramidis from BridgeBio and Eidos Therapeutics, putting some big pharma muscle behind the ther

News

Bayer takes novel deep vein thrombosis drug into phase 2

Bayer has started proof-of-concept testing of a potential new therapy for patients with deep vein thrombosis (DVT) that works in a different way to current drugs.

R&D

This week in clinical trials: 22nd to 26th January 2024

And so, our weekly clinical trials round-ups continue.

News

Bayer reaches deal on shedding management layers

After lengthy negotiations, Bayer has reached a deal with union representatives that will result in a sizeable reduction in managerial roles, part of a cost-cutting drive

Bayer cues up filings for rival to Astellas’ menopause drug

Bayer CEO pulls back from breakup of ‘badly broken’ group

Bayer pays $310m for Euro rights to ATTR therapy acoramidis

Bayer takes novel deep vein thrombosis drug into phase 2

This week in clinical trials: 22nd to 26th January 2024

Bayer reaches deal on shedding management layers

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Bayer

Editor's Picks